Alirocumab reduces dangerous coronary plaque and stabilizes high-risk lesions

Intensive LDL-C lowering with alirocumab significantly reduces high-risk coronary plaque burden, transforming unstable plaques into more stable phenotypes. This lesion-level analysis underscores the enhanced efficacy compared to vessel-level approaches.

Illumina names Agilent’s Jacob Thaysen as its next CEO

Name: Jacob Thaysen New title: CEO, Illumina Previous title: President of the life sciences and applied markets group, Agilent Technologies DNA sequencing provider Illumina has appointed

September 5, 2023

Spear Bio secures $45 million in oversubscribed Series A financing to accelerate product launch for protein research and disease diagnostics

WOBURN, Mass.–(BUSINESS WIRE)–Spear Bio Inc., a biotechnology company enabling the measurement of protein molecules down to dozens of copies with ubiquitous qPCR equipment, announced the

July 31, 2024

Philips leader signed off on sale of respiratory devices despite evidence of health risks: report

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Philips CEO Roy Jakobs approved

October 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.